SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 7,649.25 |
| Enterprise Value ($M) | 6,005.07 |
| Book Value ($M) | 5,535.97 |
| Book Value / Share | 7.76 |
| Price / Book | 1.38 |
| NCAV ($M) | 5,107.59 |
| NCAV / Share | 7.16 |
| Price / NCAV | 1.50 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.02 |
| Return on Assets (ROA) | -0.02 |
| Return on Equity (ROE) | -0.02 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 37.91 |
| Current Ratio | 37.91 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 5,363.97 |
| Assets | 5,792.35 |
| Liabilities | 256.38 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | QVT Financial LP | |||
| 13G/A | Sb Investment Advisers (uk) Ltd | |||
| 13G/A | Viking Global Investors Lp | 7.30 | -22.01 | |
| 13G | Fmr Llc | 6.64 | ||
| 13G/A | Vanguard Group Inc | 5.63 | 0.00 | |
| 13G | BlackRock, Inc. | 5.70 | 0.00 | |
| 13G/A | Sumitomo Chemical Co., Ltd. | 0.00 | -100.00 | |
| 13G/A | Dexcel Pharma Technologies Ltd. | 12.78 | 0.00 | |
| 13G/A | Ramaswamy Vivek | 9.75 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 872,114 | 3,492,375 | 24.97 | |
| 988,247 | 3,429,368 | 28.82 | |
| 598,580 | 2,202,701 | 27.17 | |
| 770,906 | 2,942,061 | 26.20 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RIGL – Rigel Pharmaceuticals, Inc. | RLMD – Relmada Therapeutics, Inc. |
| RLYB – Rallybio Corporation | RPRX – Royalty Pharma plc |
| RPTX – Repare Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io